Identification of miRNAs associated with the mechanical response of hepatic stellate cells by miRNA microarray analysis

SUHONG YI1,2*, XIA QIN1,3*, XU LUO1*, YI ZHANG4, ZHIJUN LIU2 and LIANG ZHU1

1Department of Gastroenterology, Changzheng Hospital, The Second Military Medical University, Shanghai 200003; 2Department of Gastroenterology, Xinyu People's Hospital, Xinyu, Jiangxi 338000; 3Shanghai University of Medicine and Health Sciences, Shanghai 200003; 4Department of Gastroenterology, Taizhou People’s Hospital, Taizhou, Jiangsu 225300, P.R. China

Received January 12, 2018; Accepted June 4, 2018

DOI: 10.3892/etm.2018.6384

Abstract. It has been suggested that hepatic stellate cells (HSCs) could be used in the regulation of liver microcirculation and portal hypertension. The effects of tensile strain on the microRNA (miRNA) profile of HSCs are largely unknown. In this study, we aimed to explore the changes of miRNA expression in tensile strain-treated HSCs. The purity and activation of HSCs were determined by immunofluorescence staining with antibody against desmin and α-SMA, respectively. miRNA profile analysis was performed on HSCs with and without tensile strain treatment (n=3) using microarray analysis. We identified 6 significantly differentially expressed miRNAs (DEMs), including 1 downregulated (rno-miR-125b-2-3p) and 5 upregulated (rno-miR-1224, rho-miR-188-5p, rho-miR-211-3p, rho-miR-3584-5p and rho-miR-466b-5p), which were validated by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) experiments. Further analysis of the DEMs revealed that many important biological processes and signal pathways were triggered in tensile strain-treated HSCs. These include the signal transduction mechanisms associated with protein binding, apoptosis, proliferation, and the FoxO and Wnt signaling pathways. In conclusion, this study presents the specific DEMs in tensile strain-treated HSCs. Our study provide novel miRNA-based information that may enhance our understanding of the pathophysiological processes leading to portal hypertension.

Introduction

Portal hypertension, defined as an increased pressure gradient between portal vein and hepatic veins, is the result of increased vascular resistance and portal blood flow (1,2). The causes of portal hypertension include pre-hepatic (e.g., arteriovenous fistula, portal or splenic vein thrombosis), intra-hepatic (e.g., sinusoidal obstruction syndrome, schistosomiasis and cirrhosis) and post-hepatic causes (e.g., inferior vena cava obstruction and Budd-Chiari syndrome), among which cirrhosis is the most common cause of portal hypertension (1,2). Hepatic stellate cells (HSCs) located in the perisinusoidal space of the liver accounts for 5-8% of all liver cells (3). HSCs have been considered as the main mediator of liver fibrosis (4-6) for years. Recent studies have reported that activated HSCs can contract or relax in response to various vasoactive substances [e.g., nitric oxide (7), carbon monoxide (8) and endothelin (9)] and suggested the involvement of HSCs in the regulation of liver microcirculation and portal hypertension.

MicroRNAs (miRNAs) are 21-to-23-nucleotide-long, non-coding RNA molecules. miRNAs bind to the 3’-untranslated region of target genes and negatively regulate their expression by mRNA cleavage or translational repression. Thus, miRNAs play an central role in the regulation of various cell functions such as cell proliferation, differentiation, and apoptosis (10). Some miRNAs, e.g., miR-19b (11), miR-29 (12), miR-126 (13), miR-132 (14), miR-150 (15) and miR-194 (15), have been found involved in HSC transdifferentiation and downregulated in fibrotic livers. Some studies have also been performed to investigate the association of miRNAs and portal hypertension. For example, miR-666 and miR-708 could suppress the expression of a water channel aquaporin-1, which promotes fibrosis and portal hypertension (16). Circulating miRNA-122 levels are found inversely correlated with portal pressure of patients with HIV/hepatitis C virus (HCV) coinfection (17). However, it is not known whether miRNAs play a role in the mechanical response of HSCs to portal hypertension.

In this study, tensile strain was applied to HSCs to mimic the mechanical force caused by portal hypertension. Microarray was used for miRNA profile analysis in HSCs with or without tensile strain. We characterized 6 significant differentially expressed miRNAs (DEMs) in response to tensile strain. The...
target genes of DEMs were predicted, and subjected to Gene Ontology (GO) and pathway analysis. This study may provide comprehensive information on the molecular mechanisms of portal hypertension.

Materials and methods

Isolation, culture and identification of primary HSCs. The animal experiments were approved by the Animal Care and Use Committee of the Second Military Medical University (Shanghai, China). Male Sprague-Dawley rats (10-14 weeks), weighing 400-600 g were purchased from Shanghai Experimental Animal Center (Shanghai, China). The rats were housed in a temperature controlled room (21 ± 2°C) on a 12:12-h light/dark cycle (lights on at 06:00). All rats had free access to water and food. HSCs were isolated from rat liver by in situ perfusion with 0.025% type IV collagenase and density gradient centrifugation with 12% Nycodenz (both from Sigma-Aldrich: Merck KGaA, St. Louis, MO, USA). The isolated cells (1x10⁶ cells/cm²) were plated in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS) at 37°C in 5% CO₂/95% air. The medium was replaced every other day. HSCs were quiescent within 2 days and completely activated at day 14. Cell survival was determined by trypan blue staining. The purity of HSCs was identified by immunofluorescence staining with anti-desmin (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and anti-α-SMA (Abcam, Cambridge, MA, USA).

Application of tensile strain to HSCs and RNA extraction. Activated HSCs were plated onto collagen-coated BioFlex amino-culture plates (Flexcell International, McKeessport, PA, USA) and grown in DMEM without FBS for 24 h. HSCs were then subjected to a 10% tensile strain, 0.5 Hz for 24 h by using Flexercell FX-2000 system (Flexcell International), as previously described (18).

Total RNA was extracted from HSCs with or without tensile strain treatment by using miRVana™ RNA Isolation kit (Thermo Fisher Scientific, Inc., Rockford, IL, USA) following the manufacturer's instructions. The extracted RNA was then quantified by using NanoDrop spectrophotometer (NanoDrop Technologies: Thermo Fisher Scientific, Inc., Wilmington, DE, USA) at 260 nm.

miRNA expression analysis using miRNA array. miRNA profiling was undertaken with Agilent Rat 8x15k miRNA microarray (Agilent Technologies, Inc., Santa Clara, CA, USA) containing 765 rat miRNAs annotated in miRbase version 21.0 according to the manufacturer's instructions. In brief, 100 ng total RNA was dephosphorylated, denatured and labeled with cyanine 3-pCp. Subsequently, samples were purified, dried with a vacuum concentrator and hybridized to the microarrays in Agilent SureHyb Chamber base at 55°C for 20 h. After washing, the slides were scanned with a scanner (Agilent Technologies, Inc.). The raw data were exported by Agilent Feature Extraction (FE) software. The threshold for significant DEMs was set as fold-change ≥2.0 and P<0.05.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). To validate the microarray data, RT-qPCR was performed. The extracted RNA was reverse transcribed using M-MLV Reverse Transcriptase (Thermo Fisher Scientific, Inc.) with a special stem-loop primer (RT primer). Subsequently, real-time PCR was performed with SYBR-Green PCR kit (Thermo Fisher Scientific, Inc.) on ABI PRISM 7500 Real-Time PCR system (Applied Biosystems: Thermo Fisher Scientific, Inc., Foster City, CA, USA) according to manufacturer's instructions. The sequences of RT and PCR primers are listed in Table I. The expression levels of miRNAs were normalized to U6 expression. Statistical differences were determined using Student's t-test with a threshold of P<0.05.

Target prediction of the DEMs. We used miRNAorg (http://www.microrna.org) and TargetScan (http://www.targetscan.org/) (19) to search for mRNA targets of the DEMs. The mRNA targets that were predicted by two programs were considered.

GO and pathway analysis of predicted mRNA targets. GO and pathway analysis was performed on predicted mRNA targets of the DEM using DAVID bioinformatics resources (20) and the KEGG database (21-23), respectively. Specific biological process categories and pathways were enriched. The threshold of significance was defined by P-value (<0.05) and Benjamini-Hochberg false discovery rate (FDR-bh, <0.25).

Statistical analysis. SPSS20.0 software (SPSS Chicago, IL, USA). SPSS 19.0 software (IBM, Armonk, NY, USA) was used for statistical analysis. Student’s t-test was used for comparing the variables in control and treated groups.

Results

Identification of primary HSCs. HSCs were isolated from rat liver by in situ collagenase digestion and density gradient centrifugation. The purity of HSCs was determined by immunofluorescence staining. As shown in Fig. 1, desmin, an HSC marker (24), was expressed in most cells at both day 2 and 4 after plating, suggesting the purity of HSCs. The signal of α-SMA, a marker of activated HSC (25), was not detected at day 2 and became obvious at day 14, indicating that the isolated HSCs were quiescent within 2 days and completely activated at day 14.

DEMs in response to tensile strain. To investigate the effects of mechanical force on the miRNA profile of HSCs, tensile strain was applied to the activated HSCs, and RNA was extracted and subjected to microarray analysis. A total of 765 miRNAs was examined. With a threshold of fold-change ≥2.0 and P<0.05, we identified 6 significant DEMs, including 1 downregulated (rno-miR-125b-2-3p) and 5 upregulated (rno-miR-1224, rho-miR-188-5p, rho-miR-211-3p, rho-miR-3584-5p and rho-miR-466b-5p) (Fig. 2 and Table II) in tensile strain-treated HSCs compared with control HSCs.

Validation of miRNAs microarray with RT-qPCR. To validate the microarray results, RT-qPCR was performed in tensile strain-treated HSCs and control HSCs for rno-miR-125b-2-3p, rho-miR-188-5p and rho-miR-211-3p. As shown in Fig. 3, the change trend of the 3 miRNAs detected by RT-qPCR was the same as the results of miRNA microarray.
We then searched the potential target genes of the 6 DEMs by using two bioinformatic algorithms. There were 1,449 and 4,880 target genes predicted in miRNAorg and TargetScan, respectively.

**Table I.** Primer sequences for RT-qPCR.

| Systematic name | RT primers                                                                 |
|-----------------|-----------------------------------------------------------------------------|
| rno-miR-188-5p  | 5'-CTCAACTGGTGTCGAGTGCAATTGCTGAGCCCTCCAC-3'                                |
| rno-miR-125b-2-3p | 5'-CTCAACTGGTGTCGAGTGCAATTGCTGAGCCCTCCAC-3'                               |
| rno-miR-211-3p  | 5'-CTCAACTGGTGTCGAGTGCAATTGCTGAGCCCTCCAC-3'                               |

| Systematic name | PCR primers                                                                 |
|-----------------|-----------------------------------------------------------------------------|
| rno-miR-188-5p  | 5'-ACACTCCAGCTGGGACATCGCTGCTGTGATGT-3'                                     |
| rno-miR-125b-2-3p | 5'-ACACTCCAGCTGGGACATCGCTGCTGTGATGT-3'                                    |
| rno-miR-211-3p  | 5'-ACACTCCAGCTGGGACATCGCTGCTGTGATGT-3'                                    |
| U6              | 5'-CTCGCTTCGGCAGCACA-3' and 5'-AACGCTTCACGAATTTTGCGT-3'                    |
| Universal reverse | 5'-TGGTGTCGAGTCG-3'                                                         |

RT-qPCR, reverse transcription-quantitative polymerase chain reaction.

**Figure 1.** Identification of primary cultured HSCs. Isolated HSCs were stained with (A) anti-desmin (red fluorescence) or (B) anti-α-SMA (green fluorescence) at day 2 and 14. Cell nucleus was stained with DAPI (blue fluorescence). Magnification, x200. HSCs, hepatic stellate cells.

**GO and pathway analysis.** We then searched the potential target genes of the 6 DEMs by using two bioinformatic algorithms. There were 1,449 and 4,880 target genes predicted in miRNAorg and TargetScan, respectively.
To understand the biological significance of DEMs, we conducted a functional annotation of the target genes with GO (Fig. 5) and pathway analysis (Fig. 6). By using a threshold (Fig. 4). To reduce the false positives, the target genes that were predicted in both algorithms were considered and are listed in Table III.

Table II. Differentially expressed miRNAs.

| Systematic name | FC (abs) | P-value | Active sequence | miRBase accession no. |
|-----------------|----------|---------|-----------------|-----------------------|
| **Upregulated** |          |         |                 |                       |
| rno-miR-1224    | 2.7449   | 0.0451  | CTCCACCTCCC      | MIMAT0012827          |
| rno-miR-188-5p  | 2.5143   | 0.0129  | CCCTCCACCAT      | MIMAT0005301          |
| rno-miR-211-3p  | 5.3486   | 0.0055  | CCCCTTTTGCTGTC   | MIMAT0017157          |
| rno-miR-3584-5p | 4.5451   | 0.0003  | GCCTCCTGGACTCC   | MIMAT0017875          |
| rno-miR-466b-5p | 5.6303   | 0.0071  | CATGGGACATACACACACACACAC | MIMAT005278 |
| **Downregulated** |        |         |                 |                       |
| rno-miR-125b-2-3p | -15.5835 | 0.0131  | AGGTCCCAAGAGCCT  | MIMAT0026467          |

miRNAs, microRNAs.

Figure 2. The DEMs differentiated the HSCs with (treated) and without tensile strain (control). The hierarchical clustering analysis is shown. DEMs, differentially expressed miRNAs; HSCs, hepatic stellate cells.

Figure 3. Expression of (A) rho-miR125b-2-3p, (B) rho-miR88-5p and (C) rho-mir211-3p by RT-qPCR analysis. (D) Comparison of microarray and RT-qPCR results of selected DEMs. RT-qPCR, reverse transcription-quantitative polymerase chain reaction; DEMs, differentially expressed miRNAs. Compared with control, **P<0.01; Compared with control, *** P<0.001.

Figure 4. Venn diagram of target genes predicted in miRNAorg and TargetScan.
of P<0.05 and FDR-bh<0.25, 259 GO terms were considered significant. Additionally, 64, 19 and 176 GO terms belong to cellular component, molecular function and biological process category, respectively (supplementary Tables available upon request). The target genes of DEMs were mainly enriched in the terms of membranes, protein binding, apoptosis, proliferation, response to muscle stretch and signal transduction. Through KEGG pathway analysis, we identified 17 significant KEGG pathways (Fig. 6) at a cut-off P<0.05 and FDR-bh<0.25, including diseases (pathways in cancer, colorectal cancer, Table III. Target genes of DEMs.

| Systematic name | Target genes |
|-----------------|--------------|
| rno-miR-1224    | Sorbs2, Il24, Pdpn, Dpp3, Kcnip2, Nupl1, Pkig, Fos, Pknp, Maob, Fmod, Dnm11, Ankrd1, Atf5, Cdc47, Dpe1b, Il11, Sbds, Anxa4, Tmem55a, Nsmf, Upp2, Arpc1b, Ubac2, Nipsnap3b, B3gnt7, Abcc12, Kat7, Tmem43, Camkk1, Rhobtb2, Asgrl1, Creb3, Plin2, Sumo2, Srek1ip1, Tmem150a, Mina, Sipal13, Pld1, Dagla, Rgs12, Gas7, Arpc5, Capzb, Zlh1, Rfk, Ahr, Gme1, Slc5a6, Arfgap2, Adgr4, Tmem183a, Degs1, Hmgn3, Selk, Lias, Papp2c, Ga, Cp, Cnot8, Gmcr, Tac4, Tsnap3, Apln, Mapk14, Skap1, Beclin1, Cd200, Vamp1, Cdc42pba, Nutd3, Prss8, Gpha2, Smac2ar, Narfl, Becn, P2rx2, Rab15, Knp1, Raf1, Synpr, Ndfip1, Clcn7, Gt2i2, Slc25a39, Gjb6, Smacrd2, Arl2, Pdap1, Myzap, Csf1r, Pyy, Prap1, Dyncl2, Klhi24, Syt15, Asah1, Acads, Prkag2, L1cam, Has2, Mks1, Polor1a, Parp16, Srrp1, Ap5m1, Cacnb2, Cophobia, Pol3e, Wnt4, Phhip, Pseun, Ubr7, Zch3h4, Atpv6v1b2, Zmynd19, Haa0, Stxbp1, Rnf135, Epn2, Fgr13, Il1r1, Ddx21, Gulp1, Sfrp4, Ing3, Myo1d, Skpl, Clip2, Trim9, Tpm3, Trim26, Sqtstn1, Polm, Fgl2, Pptpr, Slc46a3, Map2k6, Fbnl5, Cntn2, Klhl7, Sdcac3g, Nup210, Cntn4, Lpar1, Prpf4b, Inppl1, Rnf39, Rnf185, Cdc25a, Slc30a3, Zip422, Ik, Gtdc1, Cabs1, Calcoc1, Uc2p, Imp4, Pippi3, Tom1, Atp9a, Got2, Ppt2, Rab11a, Tor3a, Gnb3, Fut4, Chst15, Arhap2, Rpp75, Tbr1, Hnmprr, Tmem106a, Clasp2, Ctsf, Insr, Tmem176b, Fkb10, Csnk1g2, Idh3a, Stat5a, Pflg1, Hf3f3b, Gabarap2, Polr3d, Ann1, Cecd82, Uch1l, Ckn3h, Rhbg, Scdcbp, Arfgap2a1, Dnrd2, Arub4b, Zchcc12, Crat, Khdrbs2, Dhrs1, Tmem97, Igif2r, Dvll, Syx, Cd276, Elav12, Naa11, Tmem255a, Gga1, Sox10, Hyou1, Ybx3, Lrrc2, Atpv6v1g2, Lral, Tyrh |
| rno-miR-188-5p  | Gjb2, Rnf146, Sp4, Tmem43, Tb1bm, Gpnmnb, Elov6, Bcll22, Ap5m1, Hhex, Khdrbs2, Impq2, Gimap8, Casp2, Sh2d4a, Jmjcd8, Nek6, Prep, Ube2n, Efnb1, Chn, Pmp22a, Mxs1, Gira2, Crsls1, Dff4a, Snf8, I13ra1, Mal2, Gaiu11, Fiq11, Tomm70a, Cby5b5, Psmcn3ip, Thpna, Neuro1, Ckn2s2, Glg1, Cnppd1, Nip7, Rassf1, Tsnap12, I22r2a, Airl8b, Yip4f, Emp1, Selt, Clec14a, Sumo2, Tmprss5, Tbrg1, Gmpnb6, Snn, Fkpr, Lhx8, Ms4a2, Trub1, Mabf, Dynlt3, Smpdl1, Extl3, Rassf5, Kcn3p, Lpar1, Gnrh, Trak2, Ras2s, Cat, Pde4a, Slc22a3, Pts, Dcpr, Rnf185, Sqtstn1, P2rx7, Tsnap11, Pptrr, Syt1, Gpc2, Smad3, Fut1, Cecd50, Cbrd11, Thpo, Unc50, Hnfla1, Ube2i, Prps2, Pole3, Tmem505b, Klf6, Wdr45, Ing3, Zftp354a, Cdc42a2, Slep1, Rab9a, Oprim1, Cptla, Ccnd2, Armcxl, Tmem30a, Mgzat1, Cbln2, Tlrl3, Cnga2, Abec66, Trip12, Synd11, P4hb, Pkra, Garl1, Fshb, Ybx3, Lrrc2, Atpv6v1g2, Lral, Tyrh |
| rno-miR-466b-5p | Slc26a1, Hfe, Cecd82, Slc25a22, Ak2, Adk, Net1, Oprim1, Rims1, Psma4, Kcnj3, Popdc2, Ret, Nupl1, Lypla1, Caga2, Slc25a10, Slc6a3, Npxph1, Chrm5, Tagln2, Nlgn3, Gng10, Biec2, Cabs1, Pmpnc, Foxa2, Dyncl1i1, Slco2a1, Fmod, Eph7a, Chm, Polr3d, Nr3c1, Lpppr4, Aqpp4, Sp, Fam110c, Ankrd34a, Metap2, Zbx1, Gjb4, Tmem38b, Tmx1, Adlh1, Insig2, Kcnk10, Chst1, Asic4, Matr3, Capn6, Sharpin, Rbbpp7, Flot2, Vsn1l1, Rnd1, Gcnt2, Gmpna6a, Nme8, Xcr5, Ilt2, Spry2, Ilt11m, Slc35a3a, Aspn, Hmgcs1, Sod3, Dek, Lztt1l, Kcnvl1, Knap4, Srr, Cacybp, Gshr3, Cbsho1, Glnd, Rbl2, Has2, Pex3, Drd2, Dusp9, Tarcl, Chnr2, Ugtg1, Chn1, Fat2, Pleg1, Epacm, Cdc53, Casp3, Flver2, Sorbs2, Slc18a2a, Kcnq3, Xerec4, Cyb5r3, Cldln1, C1galt1c1, Hsd17b12, Psmld1, Crebphp, Ntrk2, Cd38, Bcap29, Dclkl, Pscrl3, Ctsd, Rassf5, Slc3a1, Ehd2, Cckbr, Armcx3, Bdkb2r, Chi3i1l, Yip6f6, Osgepl1, Asic2, Id1, Nefl, Sirt6, Cyb561a3, Tnx2, Slc2a13, Acs14, Sstr1, Wscdl1, Calcocol1, Traml1, P2rx1, Ennp5, Ppp1rl1a, Khdrbs2, Fbx112, Lpar1, Exco8q, Qptp, Npy5r, Rgs4, Stap1, Atad3a, Sema4f, Slc47a1, Gnb1, Gmct, Extl3, Rnls, Ube2v2, Fgl2, Gls2, Pot1, Comt, Nrg1, Arlbh, Cwb1d1, Akap7, Abhd6, Cat, Bcl2, Cryrbp, Chmp4c, Kat7, Acly, Bripn3, Prmt3, Bnsd, Cd81, Selt, Ctps2, Wars, Tcea1, Prim1, Btbd10, Cdc20, Gss, Strbp, Hrspb12, Tnfaip1, Opclm, Kpna1, Igbf7p7, Cyp11a1, Hexim1, Mafk, Slc27a1, Foxg1, Rabl2a, Slc13a3, Prkag2, Bmp4, Rhoc, Elov6, Atp2b1, Vps33b, Sbp4, Nupl1f1, Adam7 |

DEMs, differentially expressed miRNAs.
Figure 5. GO analysis based on miRNA-targeted genes. (A) Cellular component. (B) Molecular function. (C) Biological process. The histograms of significant pathways targeted by DEMs are shown. The vertical axis is the pathway category, and the horizontal axis represents $-\log (P\text{-value})$ of the pathways. GO, Gene Ontology; miRNA, microRNA; DEMs, differentially expressed miRNAs.
miRNAs in cancer, amyotrophic lateral sclerosis, and maturity onset diabetes of the young) and signaling pathway (sphingolipid, FoxO and Wnt).

Discussion

HSCs have been suggested to be involved in the regulation of liver microcirculation and portal hypertension. Recently, evidence has accumulated supporting that miRNAs are associated with liver diseases (26). However, there are few studies on the mechanical response of HSCs to portal hypertension. In this microarray study, we identified differentially expressed miRNAs in HSCs in response to tensile strain. We found that 6 miRNAs (1 downregulated and 5 upregulated) significantly differentially expressed. DEMs included those that were previously associated with liver diseases, such as alcoholic liver disease [miR-1224 (27)], HBV/HCV infection [miR-211 (28)], and liver cancer [miR-125b-2-3p (29) and miR-188-5p (30)], and others that are novel in liver diseases (miR-3584-5p and miR-466b-5p). miR-3584-5p (31) and miR-466b-5p (32) have been found involved in *S. japonicum* infection and lipopolysaccharide-induced inflammation, respectively.

Moreover, GO analysis was performed on the target mRNAs of DEMs. The results showed that the target mRNAs are involved in diverse pathophysiological processes including protein binding, cell apoptosis, cell proliferation and response to muscle stretch, which may be implicated in the reponse to tensile strain and the pathogenesis of portal hypertension. To reveal miRNA regulation of pathways, KEGG pathway analysis was performed based on the predicted target mRNAs of DEMs. Notably, FoxO and Wnt pathways were identified as significant. Constitutively active FoxO1 negatively regulates the proliferation and transdifferentiation of HSCs in liver fibrosis (33). Wnt signaling promotes hepatic fibrosis by enhancing HSC activation and survival (34,35). These previous reports have supported the critical role of FoxO and Wnt pathways in the pathogenesis of liver fibrosis. Our results suggested the possible involvement of these two pathways in the mechanical response of HSCs and in the pathogenesis of portal hypertension, although there is still much to learn about the underlying mechanisms.

In summary, we have shown the differentially expressed miRNA in tensile strain-treated HSCs. The results of GO and pathway analysis further provided novel miRNA-based information that may enhance our understanding of the pathophysiological processes leading to portal hypertension and may contribute to improving outcome for patients with portal hypertension.

Acknowledgements

Not applicable.

Funding

This study was funded by the National Natural Science Foundation of China (General Program) (11272342).

Availability of data and materials

The analyzed data sets generated during the study are available from the corresponding author on reasonable request.

Authors' contributions

SY and LZ designed the study. SY, XQ and XL performed the animal experiments. YZ and ZL performed RT-qPCR. SY, XQ, XL and LZ analyzed the RT-qPCR data. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

All animal experiments were approved by the Animal Care and Use Committee of the Second Military Medical University (Shanghai, China).
Patient consent for publication
Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Berzigotti A, Seijo S, Reverer E and Bosch J: Assessing portal hypertension in liver diseases. Expert Rev Gastronenterol Hepatol 7: 141-155, 2013.

2. Bloom S, Kemp W and Luel J: Portal hypertension: Pathophysiology, diagnosis and management. Intern Med J 45: 16-26, 2015.

3. Geerts A: History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin Liver Dis 21: 311-335, 2001.

4. Reeves HL and Friedman SL: Activation of hepatic stellate cells - a key issue in liver fibrosis. Front Biosci 7: d8088-d826, 2002.

5. Gæbele E, Brenner DA and Rippe RA: Liver fibrosis: Signals leading to the amplification of the fibrogenic hepatic stellate cell. Front Biosci 16: d6809-d727, 2011.

6. Puche JE, Saiman Y and Frieden RL: Hepatic stellate cells and liver fibrosis. Compr Physiol 3: 1473-1492, 2013.

7. Rockey DC and Chung JJ: Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: Endothelial dysfunction in portal hypertension. Gastroenterology 114: 344-351, 1998.

8. Suematsu M, Goda N, Sano T, Kashwagi S, Egawa T, Shinoda Y and Ishimura Y: Carbon monoxide: An endogenous modulator of sinusoidal tone in the perfused rat liver. J Clin Invest 96: 2431-2437, 1995.

9. Fallowfield JA, Hayden AL, Snowden VK, Aucott RL, Stuchfield BM, Mole DJ, Pellicoro A, Gordon-Walker TT, Fallowfield JA, Mole DJ, Pellicoro A, Gordon-Walker TT: Relaxin modulates human and rat hepatic myofibroblast function and ameliorates portal hypertension in vivo. Hepatology 59: 1492-1504, 2014.

10. He Y, Huang C, Zhang SP, Sun X, Long XR and Li J: The potential of microRNAs in liver fibrosis. Cell Signal 24: 2268-2272, 2012.

11. Lakner AM, Steuerwald WM, Walling TL, Ghosh S, Li T, McKillop IH, Russo MW, Bonkovsky HL and Schrum LW: Inhibitory effects of microRNA 19b in hepatic stellate cell-mediated fibrogenesis. Hepatology 56: 300-310, 2012.

12. Roderburg C, Urban GW, Betterment K, Vucur M, Zimmemann H, Schmidt S, Janssen J, Kopppe C, Knolle P, Castoldi M, et al: Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology 53: 209-218, 2011.

13. Guo CJ, Pan Q, Xiong H, Qiao YQ, Bian ZL, Zhong W, Sheng L, Li H, Shen L, Hua J, et al: Dynamic expression of miR-126 and its effects on proliferation and contraction of hepatic stellate cells. FEBS Lett 587: 3792-3801, 2013.

14. Mann J, Chu DC, Maxwell A, Oakley F, Zhu NL, Tsukamoto H and Mann DA: MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis. Gastroenterology 138: 705-714, 2010.

15. Venugopal SK, Jiang J, Kim TH, Li Y, Wang SS, Torok NJ, Wu J and Zern MA: Liver fibrosis causes downregulation of miRNA-150 and miRNA-194 in hepatic stellate cells, and their overexpression causes decreased stellate cell activation. Am J Pathol 179: 1851-1860, 2011.

16. Haeber R, Jagavelu K, Hendrickson H, Yasdev MM, Arab JP, Splinter PL, Trussoni CE, Larusso NF and Shah VH: Aquaporin-1 promotes angiogenesis, fibrosis, and portal hypertension through mechanisms dependent on osmotically sensitive microRNAs.

17. Jansen C, Reiberger T, Huang J, Eischei H, Schierwagen R, Manderor M, Anadol E, Schwabl P, Schwarze-Zander C, Warnecke Eber U, et al: Circulating miRNA-122 levels are associated with hepatic necroinflammation and portal hypertension in HIV/HCV coinfection. PLoS One 10: e0116768, 2015.

18. Yi SH, Zhang Y, Tang D and Zhu L: Mechanical force and tensile strain activated hepatic stellate cells and inhibited retinol metabolism. Biotechnol Lett 37: 1141-1152, 2015.

19. Liang BS, Shih HH, Jones-Rhoades MW, Bartel DP and Burge CB: Prediction of mammalian microRNA targets. Cell 115: 787-798, 2003.

20. Huang W, Sherman BA and Lempicki RA: Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37: 1-13, 2009.

21. Kanelisa M, Goto S, Kawashima S, Okuno Y and Hattori M: The KEGG resource for deciphering the genome. Nucleic Acids Res 32: D277-D280, 2004.

22. Yi C, Morton JD, Cohen JC, Hobbs HH and Stephens RM: WholePathwayScope: A comprehensive pathway-based analysis tool for high-throughput data. BMC Bioinformatics 7: 30, 2006.

23. Draghici S, Khatri P, Arca LA, Amin D, Voicu C, Georgescu C and Romero R: A systems biology approach for pathway level analysis. Genome Res 17: 1537-1545, 2007.

24. Baba S, Fuji H, Hirose T, Yasuhashi K, Azuma H, Hoppo T, Naito M, Machimizo T and Imai K: Commitment of bone marrow cells to hepatic stellate cells in mice. J Hepatol 40: 255-260, 2004.

25. Di Sario A, Bendia E, Macarri G, Candelaresi C, Tafetiani S, Marizioni M, Omenetti A, De Minicis S, Trozzi L and Benedetti A: The anti-fibrotic effect of rifenidine in rat liver fibrosis is mediated by downregulation of procollagen alpha1(I), TIMP-1 and MMP-2. Dig Liver Dis 36: 744-751, 2004.

26. Szabo G and Bala S: MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol 10: 542-552, 2013.

27. Dolganuic A, Petrashek J, Kodys K, Catalano D, Mandrekar P, Velayuthum A and Szabo G: MicroRNA expression profile in Lieber-DeCarli diet-induced alcoholic and methionine choline deficient diet-induced nonalcoholic steatohepatitis models in mice. Alcohol Clin Exp Res 33: 1704-1710, 2009.

28. Ura S, Honda M, Yamashita T, Ueda T, Takatori H, Nishino R, Sunakozaka H, Sakai Y, Htormto K and Kaneko S: Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology 49: 1098-1112, 2009.

29. Navon R, Wang H, Steinfield I, Tsalenko A, Ben-Dor A and Yakhini Z: Novel rank-based statistical methods reveal microRNAs with differential expression in multiple cancer types. PLoS One 4: e8003, 2009.

30. Fang F, Chang RM, Yu L, Lei X, Xiao S, Yang H and Yang LY: MicroRNA-188-5p suppresses tumor cell proliferation and metastasis by directly targeting FGF5 in hepatocellular carcinoma. J Hepatol 63: 874-885, 2015.

31. Han H, Peng J, Hong Y, Zhang M, Han Y, Fu Z, Shi Y, Xu J, Tao J and Lin J: Comparison of the differential expression miRNAs in Wistar rats before and 10 days after S. japonicum infection. Parasit Vectors 6: 120, 2013.

32. Hsieh CH, Rau CS, Jeng JC, Chen YC, Lu TH, Wu CJ, Wu YC, Tseng SL and Yang JC: Whole blood-derived microRNA signatures in mice exposed to lipopolysaccharides. J Biomed Sci 19: 62, 2012.

33. Adachi M, Osawa Y, Uchimari H, Kitamura T, Accili D and Brenner DA: The forkhead transcription factor FoxO1 regulates proliferation and transdifferentiation of hepatic stellate cells. Gastroenterology 132: 1434-1446, 2007.

34. Jiang F, Parsons CJ and Stefanovic B: Gene expression profile of quiescent and activated rat hepatic stellate cells implicates Wnt signaling pathway in activation. J Hepatol 45: 401-409, 2006.

35. Myung SJ, Yoon JH, Gwak GY, Kim W, Lee JH, Kim RM, Shin CS, Jang JJ, Lee SH, Lee SM, et al: Wnt signaling enhances the activation and survival of hepatic stellate cells. FEBS Lett 581: 2954-2958, 2007.